ArticleClinical research in cardiology : official journal of the German Cardiac Society2018
Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrillation.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1.Frontiers in cardiovascular medicine · 2023Review
- The interplay between autonomic tone and atrial arrhythmias.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022Article
- Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies.Nature reviews. Cardiology · 2019Review
- Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is an important, modifiable risk factor for the development of atrial fibrillation (AF). Even after pulmonary vein isolation (PVI), 20-40% experience recurrent AF. Animal studies have shown that renal denervation (RDN) reduces AF inducibility. One clinical study with important limitations suggested that RDN additional to PVI could reduce recurrent AF.
objectiveThe goal of this multicenter randomized controlled study is to investigate whether RDN added to PVI reduces AF recurrence.
methodsThe main end point is the time until first AF recurrence according to EHRA guidelines after a blanking period of 3 months. Assuming a 12-month accrual period and 12 months of follow-up, a power of 0.80, a two-sided alpha of 0.05 and an expected drop-out of 10% per group, 69 patients per group are required. We plan to randomize a total of 138 hypertensive patients with AF and signs of sympathetic overdrive in a 1:1 fashion. Patients should use at least two antihypertensive drugs. Sympathetic overdrive includes obesity, exercise-induced excessive blood pressure (BP) increase, significant white coat hypertension, hospital admission or fever induced AF, tachycardia induced AF and diabetes mellitus. The interventional group will undergo PVI + RDN and the control group will undergo PVI.
resultsPatients will have follow-up for 1 year, and continuous loop monitoring is advocated.
conclusionThis randomized, controlled study will elucidate if RDN on top of PVI reduces AF recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.